Incorporation of Host Complement Regulatory Proteins into Newcastle Disease Virus Enhances Complement Evasion

Safety and Clinical Usage of Newcastle Disease Virus in Cancer Therapy

(2011) Han Yuen Lam et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Evaluation of the Newcastle Disease Virus F and HN Proteins in Protective Immunity by Using a Recombinant Avian Paramyxovirus Type 3 Vector in Chickens

(2011) S. Kumar et al.   JOURNAL OF VIROLOGY

An Intravenous Stimulus Package for Oncolytic Virotherapy

(2011) Richard Vile et al.   MOLECULAR THERAPY

Redemption for the Field of Oncolytic Virotherapy

(2011) David H Kirn   MOLECULAR THERAPY

Recent deal highlights hopes for cancer-killing viruses

(2011) Jon Evans   NATURE MEDICINE

Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: No shortcuts on the road to approval

(2010) Caroline J. Breitbach et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Novel oncolytic viruses: Riding high on the next wave?

(2010) Marianne M. Stanford et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Acquisition of Complement Resistance through Incorporation of CD55/Decay-Accelerating Factor into Viral Particles Bearing Baculovirus GP64

(2010) Y. Kaname et al.   JOURNAL OF VIROLOGY

The Case of Oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon

(2009) Robin J. Prestwich et al.   HUMAN GENE THERAPY

Efficient fluorescence-based imaging methods for quantitating infectivity and oncolytic efficacy of Newcastle disease virus

(2009) K. Sen Sharma et al.   JOURNAL OF VIROLOGICAL METHODS

The Paramyxoviruses Simian Virus 5 and Mumps Virus Recruit Host Cell CD46 To Evade Complement-Mediated Neutralization

(2009) J. B. Johnson et al.   JOURNAL OF VIROLOGY

Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus

(2008) John B. Johnson et al.   VIROLOGY